医療ガバナンス研究所
理事長上昌広SNS
製薬マネー論文
A collaboration between physicians and journalists to create unbiased health information
No.
Date:
Title:
42
Authors:
Senoo Y, Ozaki A, Watanabe M, Tanimoto T
First Author:
Senoo Y
Journal/Book:
BMJ
URL:
Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
No.
Date:
Title:
41
Authors:
Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H, Sawano T, Yamashita E, Tanimoto T, Ozaki A
First Author:
Kusumi E
Journal/Book:
Blood Cancer J
URL:
An Assessment of adherence to the WHO-delineated Good Manufacturing Practice by the pharmaceutical companies in Kabul, Afghanistan
No.
Date:
Title:
40
Authors:
Roien R, Shrestha R, Yadav K, Ozaki A, Ahmadi MB, kaneda Y, Kotera Y, Sapkota B, Shrestha S
First Author:
Roien R
Journal/Book:
Cost Effectiveness and Resource Allocation
URL:
The Diovan scandal in Japan; don’t let bygones be bygones
No.
Date:
Title:
39
Authors:
Murata N, Ozaki A, Murayama A, Sawano T, Tanimoto T
First Author:
Murata N
Journal/Book:
J Hum Hypertens
URL:
Awareness and perceptions among members of a Japanese cancer patient advocacy group concerning the financial relationships between the pharmaceutical industry and physicians
No.
Date:
Title:
38
Authors:
Murayama A, Senoo Y, Harada K, Kotera Y, Saito H, Sawano T, Suzuki Y, Tanimoto T, Ozaki A
First Author:
Murayama A
Journal/Book:
IJERPH
URL:
Generic Medicine and Generic Prescribing in Nepal: An implication for policymakers
No.
Date:
Title:
37
Authors:
Shrestha R, Shrestha S, Sapkota B, Thapa S, Ansari M, Khatiwada AP, Roien R, Ozaki A
First Author:
Shrestha R
Journal/Book:
Journal of Multidisciplinary Healthcare
URL:
How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
No.
Date:
Title:
35
Authors:
Ozaki A, Murayama A, Harada K, Saito H, Sawano T, Tanimoto T, Ozieranski P
First Author:
Ozaki A
Journal/Book:
Frontiers in Public Health
URL:
Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of Recommendations
No.
Date:
Title:
34
Authors:
Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T
First Author:
Murayama A
Journal/Book:
HEPATOLOGY
URL:
Evaluation of Financial Conflicts of Interest and Drug Statements in the Coronavirus Disease 2019 Clinical Practice Guideline in Japan
No.
Date:
Title:
33
Authors:
Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A
First Author:
Hashimoto T
Journal/Book:
Clin Microbiol Infect
URL:
How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
No.
Date:
Title:
36
Authors:
Ozaki A, Murayama A, Harada K, Saito H, Sawano T, Tanimoto T, Ozieranski P
First Author:
Ozaki A
Journal/Book:
Front Public Health
URL:
Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis
No.
Date:
Title:
31
Authors:
Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T
First Author:
Murayama A
Journal/Book:
Otolaryngol Head Neck Surg
URL:
Japan’s conditional early approval program for innovative cancer drugs: Comparison of the regulatory processes with the US FDA and the EMA
No.
Date:
Title:
30
Authors:
Murayama A, Ueda M, Shrestha S, Tanimoto T, Ozaki A
First Author:
Murayama A
Journal/Book:
Cancer Cell
URL:
The Coverage in England of US-Approved Cancer Drugs
No.
Date:
Title:
29
Authors:
Hashimoto T, Ozaki A, Tanimoto T
First Author:
Hashimoto T
Journal/Book:
JAMA Internal Medicine
URL:
A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib
No.
Date:
Title:
32
Authors:
Kidoguch K, Shibusawa M, Tanimoto T
First Author:
Kidoguch K
Journal/Book:
Invest New Drugs
URL:
Industry Payments to Medical Oncologists
No.
Date:
Title:
28
Authors:
Hashimoto T, Ozaki A, Tanimoto T
First Author:
Hashimoto T
Journal/Book:
JAMA Oncology
URL:
Japan’s Drug Regulation During the COVID‐19 Pandemic: Lessons From a Case Study of Favipiravir
No.
Date:
Title:
27
Authors:
Ueda M, Tanimoto T, Murayama A, Ozaki A, Kami M
First Author:
Ueda M
Journal/Book:
Clin Pharmacol Ther
URL:
Opioids: A ‘crisis’ of too much or not enough – or simply how rich you are and where you live?
No.
Date:
Title:
26
Authors:
Miyachi T, Ozaki A, Saito H, Sawano T, Tanimoto T, Crump A
First Author:
Miyachi T
Journal/Book:
Eur J Pain
URL:
Whistleblowing and Misconduct at Large Pharmaceutical Firms
No.
Date:
Title:
25
Authors:
Hashimoto T, Ozaki A, Tanimoto T
First Author:
Hashimoto T
Journal/Book:
The Journal of the American Medical Association
URL:
Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension
No.
Date:
Title:
24
Authors:
Senoo Y, Hiroaki S, Ozaki A, Sawano T, Shimada Y, Yamamoto K, Suzuki Y, Tanimoto T
First Author:
Senoo Y
Journal/Book:
Medicine
URL:
Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017
No.
Date:
Title:
23
Authors:
Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A, Senoo Y, Tanimoto T
First Author:
Harada K
Journal/Book:
Health Policy
URL:
Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017
No.
Date:
Title:
22
Authors:
Kayo Harada, Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Kana Yamamoto, Anju Murayama, Yuki Senoo, Tetsuya Tanimoto
First Author:
Kayo Harada
Journal/Book:
Health Policy
URL:
Covid-19 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies.
No.
Date:
Title:
20
Authors:
Anju Murayama, Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Ranjit Sah, Tetsuya Tanimoto
First Author:
Anju Murayama
Journal/Book:
Clinical Microbiology and Infection
URL:
Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment
No.
Date:
Title:
21
Authors:
Kida Futa, Anju Murayama, Hiroaki Saito, Akihiko Ozaki, Yuki Shimada, Tetsuya Tanimoto
First Author:
Kida Futa
Journal/Book:
Liver International
URL:
Pharmaceutical good manufacturing practice: Leuplin® production in Japan identifies major international shortcomings
No.
Date:
Title:
23
Authors:
Masahiro Wada, Akihiko Ozaki, Takashi Miyachi, Tetsuya Tanimoto, Andy Crump
First Author:
Masahiro Wada
Journal/Book:
Investigational New Drugs
URL:
Transparency is not enough: how can we improve the management of financial conflicts of interest between Pharma and healthcare domains?
No.
Date:
Title:
19
Authors:
Akihiko Ozaki, Anju Murayama, Hiroaki Saito, Toyoaki Sawano, Kayo Harada, Yuki Senoo, Kana Yamamoto, Tetsuya Tanimoto
First Author:
Akihiko Ozaki
Journal/Book:
Clinical Pharmacology & Therapeutics
URL:
Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan
No.
Date:
Title:
17
Authors:
Kana Yamamoto, Anju Murayama, Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Tetsuya Tanimoto
First Author:
Kana Yamamoto
Journal/Book:
International Urogynecology Journal
URL:
Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
No.
Date:
Title:
16
Authors:
Anju Murayama, Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Yuki Shimada, Kana Yamamoto, Yosuke Suzuki, Tetsuya Tanimoto
First Author:
Anju Murayama
Journal/Book:
PLOS ONE
URL:
Accuracy of post-publication Financial Conflict of Interest corrections in medical research: a secondary analysis of pharmaceutical company payments to the authors of the CREATE-X trial report in the New England Journal of Medicine
No.
Date:
Title:
18
Authors:
Akihiko Ozaki, Hiroaki Saito, Toyoaki Sawano, Yuki Shimada, Tetsuya Tanimoto
First Author:
Akihiko Ozaki
Journal/Book:
Bioethics
URL:
Response to "Strictness and Transparency in Approval Process of Medical Products: Japanese Situation"
No.
Date:
Title:
15
Authors:
Toyoaki Sawano, Akihiko Ozaki, Hiroaki Saito, Yuki Shimada, Tetsuya Tanimoto
First Author:
Toyoaki Sawano
Journal/Book:
Clinical Pharmacology & Therapeutics
URL:
Overview and Transparency of Non-research Payments to Healthcare Organizations and Healthcare Professionals from Pharmaceutical Companies in Japan: Analysis of Payment Data in 2016
No.
Date:
Title:
14
Authors:
Akihiko Ozaki, Hiroaki Saito, Yuki Senoo, Toyoaki Sawano, Yuki Shimada, Yurie Kobashi, Kana Yamamoto, Yosuke Suzuki, Tetsuya Tanimoto
First Author:
Akihiko Ozaki
Journal/Book:
Health Policy
URL:
Pharmaceutical company payments to Japanese government drug regulation committee members
No.
Date:
Title:
13
Authors:
Sawano T, Ozaki A, Saito H, Shimada Y, Tanimoto T
First Author:
Toyoaki Sawano
Journal/Book:
Clinical Pharmacology & Therapeutics
URL:
Pharmaceutical Company Payments to the Professors of Orthopaedic Surgery Departments in Japan
No.
Date:
Title:
12
Authors:
Hiroaki Saito, Akihiko Ozaki, Toyoaki Sawano, Yuki Shimada, Kana Yamamoto, Yosuke Suzuki, Tetsuya Tanimoto
First Author:
Hiroaki Saito
Journal/Book:
Journal of Bone and Joint Surgery
URL:
Japan's drug regulation framework: aiming for better health or bigger profits
No.
Date:
Title:
11
Authors:
Akihiko Ozaki, Yuki Senoo, Hiroaki Saito, Andy Crump, Tetsuya Tanimoto
First Author:
Akihiko Ozaki
Journal/Book:
International Journal of Health Policy and Management
URL:
Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
No.
Date:
Title:
10
Authors:
Yurie Kobashi, Makoto Watanabe, Hideaki Kimura, Asaka Higuchi, Akihiko Ozaki
First Author:
Yurie Kobashi
Journal/Book:
International Journal of Health Policy and Management
URL:
Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis
No.
Date:
Title:
9
Authors:
Akihiko Ozaki, Hiroaki Saito, Yosuke Onoue, Toyoaki Sawano, Yuki Shimada, Yurie Somekawa, Aritsune Tsuji, Tetsuya Tanimoto
First Author:
Akihiko Ozaki
Journal/Book:
BMJ Open
URL:
Financial ties between authors of the clinical practice guidelines and pharmaceutical companies: an example from Japan
No.
Date:
Title:
8
Authors:
Hiroaki Saito, Yuta Tani, Akihiko Ozaki, Toyoaki Sawano, Yuki Shimada, Kana Yamamoto, Tetsuya Tanimoto
First Author:
Hiroaki Saito
Journal/Book:
Clinical Microbiology and Infection
URL:
Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan
No.
Date:
Title:
7
Authors:
Toyoaki Sawano, Akihiko Ozaki, Hiroaki Saito, Yuki Shimada, Tetsuya Tanimoto
First Author:
Toyoaki Sawano
Journal/Book:
JAMA Network Open
URL:
Transparency of clinical evidence for medical devices in Europe
No.
Date:
Title:
6
Authors:
Tetsuya Tanimoto, Hiroaki Saito, Toyoaki Sawano, Yuki Shimada, Akihiko Ozaki
First Author:
Tetsuya Tanimoto
Journal/Book:
Lancet
URL:
Evaluation of pharmaceutical company payments and conflict of interest disclosures among oncology clinical practice guideline authors in Japan
No.
Date:
Title:
5
Authors:
Hiroaki Saito, Akihiko Ozaki, Toyoaki Sawano, Yuki Shimada, Tetsuya Tanimoto
First Author:
Hiroaki Saito
Journal/Book:
JAMA Network Open
URL:
Pharmaceutical company payments to executive board members of professional medical associations in Japan
No.
Date:
Title:
4
Authors:
Hiroaki Saito, Akihiko Ozaki, Yasuma Kobayashi, Toyoaki Sawano, Tetsuya Tanimoto
First Author:
Hiroaki Saito
Journal/Book:
JAMA Internal Medicine
URL: